Novartis: Buy Rating Reiterated on Q2 Beat, Strong Growth Brands and Pipeline Upside; Price Target Maintained at $140
Complete. Here is the key summaryBank of America Securities reiterated a Buy rating on Novartis with a $140 price target, citing Q2 earnings beats, strong growth brands (Cosentyx, Kesimpta), and pipeline upside. Deutsche Bank also maintained a Buy rating with the same CHF140 target, reflecting confidence in the company's mid-single-digit sales growth and favorable long-term profile.
In a report released yesterday, Sachin Jain from Bank of America Securities reiterated a Buy rating on Novartis AG, with a price target of CHF140.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Sachin Jain has given his Buy rating due to a combination of factors, including Novartis’ solid second-quarter performance and stable guidance. The company delivered a notable earnings beat driven by stronger-than-expected core operating income, while confirming its full‑year outlook with continued mid‑single‑digit sales growth and mid‑to‑high single‑digit core operating income expansion in the second half.
He also highlights robust momentum in key growth brands such as Rhapsody, Cosentyx, Scemblix and Kesimpta, which more than offset softer trends in Entresto, Pluvicto and Kisqali. In addition, Jain sees meaningful upside from multiple late‑stage pipeline readouts across remibrutinib, del-desiran, del-brax and pelacarsen, supporting a favorable long‑term growth profile and justifying his unchanged price target of $140.
In another report released on July 17, Deutsche Bank also maintained a Buy rating on the stock with a CHF140.00 price target.